Introduction {#ss1}
============

Primary hepatocellular carcinoma (HCC) is the third leading cause of death from cancers, with an estimated 549,000 deaths per year, which ranks it as the fifth most frequent malignancy worldwide ([@CIT0001]). The carcinogenesis and progression of HCC are typical of a multistage process. It has been well noted that infection with hepatitis B and C virus (HBV and HCV) is the main etiological factor for the development of HCC ([@CIT0001]). The progression is considered to affect the expression of genes that are critical to cellular processes such as cell cycle control, apoptosis, cell migration and invasion ([@CIT0009]). Many reports have emphasized the investigation of genes and proteins underlying the progress of HCC; however, their sensitivity and specificity are imperfect ([@CIT0016]). Therefore, new biomarkers are urgently required to understand factors causing hepatocarcinogenesis and to link diverse phenotypes in clinical features and prognosis. More vitally, the identification of new biomarkers is needed to predict response possibilities to different therapeutic methods.

MicroRNA (miRNA) has become a global concern for cancer research. These small, non-coding RNAs can inhibit target gene expression by binding the 3'-untranslated region (3'-UTR) of target mRNA, resulting in either mRNA degradation or inhibition of translation to protein. MicroRNAs play critical roles in many normal biological processes involving cell proliferation, differentiation, apoptosis, and stress resistance ([@CIT0017]). Studies have also revealed that aberrant miRNA expression is correlated with the development and progression of cancers. Thus, miRNAs could be utilized as biomarkers for diagnosis and prognosis prediction of cancers. Furthermore, miRNAs can have oncogenic or tumor suppressor characteristics ([@CIT0020]).

Extensive profiling studies over recent years have shown that a variety of miRNAs are abnormally expressed in HCC ([@CIT0025]). Nevertheless, there remains a lot to understand as regards the involvement of miRNAs in hepatocarcinogenesis and progression of HCC. Among all the HCC-related miRNAs, miR-146a was reported to be increasingly expressed in serum samples of HCC patients, compared with healthy controls ([@CIT0030]). However, an inconsistent expression level of miR-146a in HCC tissue samples was observed by Karakatsanis et al. ([@CIT0031]). MicroRNA-146a expression was lower in HCC than that in normal liver tissues. In the present study, we investigated the expression of miRNA-146a in HCC and their matched adjacent non-cancerous liver tissues in formalin-fixed paraffin-embedded (FFPE) surgically resected samples. Moreover, we studied the correlation between miR-146a levels and different clinicopathological parameters of HCC.

Materials and methods {#ss2}
=====================

Tissue samples {#ss3}
--------------

This retrospective study included 85 cases of HCCs and their paired paraneoplastic liver FFPE tissues. The age of the HCC patients ranged from 29 to 82 years old, with a mean age of 52 years. Clinicopathological information provided from medical records has been summarized in [Table I](#T1){ref-type="table"}. Adjacent non-cancerous liver tissues were at least 2 cm away from the tumor node. All cases were initial hepatectomies without treatment and were randomly selected from hepatectomies performed over a 1--2 year span in the First Affiliated Hospital of Guangxi Medical University, P. R. China between March 2010 and June 2011. The study protocol was approved by the Ethical Committee of the First Affiliated Hospital of Guangxi Medical University. Written informed consent was obtained from the patients and clinicians for the usage of the samples for research. All samples were reviewed and diagnosed by two independent pathologists.

###### 

Relationship between the expression of miR-146a and clinicopathological features in HCC .

  Clinicopathological features                                          *n*           MiR-146a relevant expression                                           
  ------------------------------ -------------------------------------- ------------- ------------------------------ --------------------------------------- ----------
  Tissue                         HCC                                    85            0.76 ± 0.53                    --5.532[^a^](#T1_1){ref-type="fn"}      \< 0.001
  Adjacent non-cancerous liver   85                                     1.30 ± 0.71                                                                          
  Age                            ≥50 y                                  40            0.72 ± 0.50                    --0.729                                 0.468
  \<50 y                         45                                     0.80 ± 0.55                                                                          
  Gender                         Male                                   69            0.68 ± 0.47                    --2.447                                 0.024
  Female                         16                                     1.11 ± 0.65                                                                          
  Differentiation                Well                                   5             0.47 ± 0.35                    *F* = 1.01[^b^](#T1_2){ref-type="fn"}   0.369
  Moderately                     55                                     0.81 ± 0.57                                                                          
  Poorly                         25                                     0.72 ± 0.45                                                                          
  Clinical TNM stage             I--II                                  22            1.24 ± 0.56                    4.918                                   \< 0.001
  III--IV                        63                                     0.60 ± 0.40                                                                          
  Metastasis                     Yes                                    36            0.49 ± 0.36                    --4.498                                 \< 0.001
  No                             49                                     0.96 ± 0.55                                                                          
  With cirrhosis                 Yes                                    43            0.72 ± 0.54                    --0.815                                 0.417
  No                             42                                     0.81 ± 0.52                                                                          
  AFP (μg/L)                     ≥400                                   32            0.73 ± 0.57                    --0.62                                  0.537
  \<400                          36                                     0.81 ± 0.57                                                                          
  Portal vein tumor embolus      Yes                                    23            0.47 ± 0.37                    --3.338                                 0.001
  No                             62                                     0.87 ± 0.54                                                                          
  Tumor capsular infiltration    No capsular or capsular infiltration   42            0.66 ± 0.44                    --1.763                                 0.081
  No capsular infiltration       43                                     0.86 ± 0.59                                                                          
  Tumor nodes                    Multi                                  35            0.56 ± 0.37                    --3.173                                 0.002
  Single                         50                                     0.91 ± 0.58                                                                          
  Tumor diameter (cm)            ≥5                                     69            0.73 ± 0.53                    --1.122                                 0.265
  \<5                            16                                     0.90 ± 0.57                                                                          

Paired *t* student\'s test was performed.

One-way analysis of variance (ANOVA) test was performed.

RT-qPCR {#ss4}
-------

Total RNA including miRNA was extracted from tumor sections using the miRNeasy FFPE Kit (QIAGEN, KJ Venlo, the Netherlands) according to our previous reports ([@CIT0032]). RNA concentrations were determined by NanoDrop 2000 (Wilmington, DE, USA). A combination of RUN6B and RUN48 was the housekeeping genes for detection of miR-146a expression ([@CIT0033]). The primers for miR-146a, RNU6B and RNU48, were included in TaqMan® MicroRNA Assays (4427975, Applied Biosystems, Life Technologies, Grand Island, NY, USA). Sequence of miRNA and references used in the paper are as follows: miR-146a (Applied Biosystems Cat. No. 4427975-000468): UGAGAACUGAAUUCCAUGGGUU; RNU6B (Applied Biosystems Cat. No. 4427975-001093): CGCAAGGAUGACACGCAAAUUCGUGAAGCGUUCCAUAUUUUU; RNU48 (Applied Biosystems Cat. No. 4427975-001006): GAUGACCCCAGGUAACUCUGAGUGUGUCGCUGAUGCCAUCACCGCAGCGCUCUGACC. The reverse primers were also used for reverse transcription with TaqMan® MicroRNA Reverse Transcription Kit (4366596, Applied Biosystems, Life Technologies, Grand Island, NY, USA) in a total volume of 10 μL. Real-time qPCR for miRNA was performed with Applied Biosystems PCR7900. The miR-146a abundance in each sample was normalized to its references. The expression of miR-146a in the FFPE experiments was calculated with the formula 2^-Δcq^ ([@CIT0032]).

Statistical analysis {#ss5}
--------------------

SPSS 19.0 (Munich, Germany) was used for statistical analysis. Results were representative of three independent experiments unless otherwise stated. Values were presented as the mean ± standard deviation (SD). Student\'s paired or unpaired *t* test was used to analyze significance between paired or unpaired groups. One-way analysis of variance (ANOVA) test was used to analyze significance between groups of various differentiation. Statistical significance was determined at a *p* \< 0.05 level.

Results {#ss6}
=======

Expression of miR-146a in the HCC tissues was lower than that in the adjacent non-cancerous hepatic tissues ([Table I](#T1){ref-type="table"}). Female patients had a higher miR-146a expression than male patients. With regard to clinical TNM stages, miR-146a expression in early stages (I and II) was remarkably higher than that in advanced stages (III and IV). Lower levels of miR-146a were found in HCC patients with metastasis, portal vein tumor embolus, and multiple tumor nodes, compared with patients without corresponding traits. In addition, miR-146a expression was higher in patients with a single tumor node than in those with multiple tumor nodes. However, there was no correlation between miR-146a expression and other clinicopathological features, for instance, age, histological differentiation grades, cirrhosis, plasma AFP concentrations, tumor capsular infiltration, or tumor size.

Discussion {#ss7}
==========

The distinction of miR-146a expression between HCC tissues and non-cancerous liver tissues has only been reported once ([@CIT0031]). Using real-time RT-qPCR, miR-146a expression was found to be down-regulated in HCC tissues (60 cases) compared with that in healthy controls (98 cases). The average fold change of miR-146a expression between HCC and normal liver tissues was 0.13 (HCC/normal) ([@CIT0031]). In the present study, consistent underexpression of miR-146a in HCC tissues was also observed, as compared with the corresponding adjacent liver tissues in the same patients. The results of our study, together with those of Karakatsanis et al. ([@CIT0031]), indicate that miR-146a plays a critical role in the hepatocarcinogenesis, as a tumor suppressor miRNA. However, the average fold change of miR-146a level varied (0.13 versus 0.58). The various controls selected by Karakatsanis et al. ([@CIT0031]) and our group (healthy liver tissues versus corresponding non-cancerous liver tissues) may partially explain the disparity. It might be that the miR-146a expression is lower in non-cancerous liver tissue of HCC patients than in liver tissue of healthy controls. It might also be of interest to investigate the dynamic change of miR-146a expression in the hepatocarcinogenesis and progression of HCC. For instance, a comparison of the miR-146a levels in normal liver, cirrhotic tissue, adjacent non-cancerous liver, and HCC tissues would be worthwhile to pursue. Zhu et al. ([@CIT0036]) reported that the expression of miR-146a was up-regulated in HUVECs co-cultured with a HCC cell line HCCLM3 compared with HUVECs alone. The miR-146a expression of endothelial cells (ECs) in HCC tissues might also be different. However, this remains to be investigated. We compared the miR-146a level of pure HCC cells from various cell lines (HepG2, HepB3, SNU449, and SMMC7211) with adjacent non-cancerous hepatic tissues without micrangiums by means of CD34 immunostaining (data not shown). Indeed, we found lower miR-146a expression in the HCC cells. This further confirmed the idea that there is down-regulation of miR-146a in HCC tissues.

MicroRNAs can also be identified in serum and plasma in a remarkably stable form, which makes it possible to determine the expression of miRNAs in blood samples ([@CIT0037]). Gui et al. ([@CIT0030]) profiled the circulating miRNAs in seven serum pools (two normal controls, two liver cirrhosis, and three HCC pools) using TaqMan Human MicroRNA Array. MicroRNA-146a was present in a relatively high abundance in serum samples of HCC and cirrhosis patients when compared with normal controls. Gui et al. ([@CIT0030]) failed to validate their elevation in a set of serum samples of HCC and liver cirrhosis patients using real-time RT-qPCR. A probable reason for this discrepancy is the variation between the two approaches (microRNA array versus real-time RT-qPCR). However, the cause of the divergence between the miR-146a level in HCC tissues and serum has not been clarified. Further studies will be needed to analyze the relationship of miR-146a expression between HCC tissue and serum samples and to figure out potential mechanisms.

It has previously been shown that SNPs rs2910164 in miR-146a were associated with an increased susceptibility to HCC in an Asian population ([@CIT0039]). The location of rs2910164 is the stem region opposite to the mature miR-146a sequence, which results in a change from G:U pair to C:U mismatch in the stem structure of the miR-146a precursor. Xu et al. reported that the G allele miR-146a precursor displayed increased production of mature miR-146a compared with the C-allele ([@CIT0041]). We also performed a PCR-based restriction fragment length polymorphism assay to investigate the relationship between genetic polymorphism in miRNA precursors and miRNA expression in a larger cohort including the 85 cases (data not shown). Among the 85 cases, 29 cases (34.1%) were CC genotype, 42 (49.4%) were GC genotype, and 14 (16.5%) were GG genotype. No relationship was found between different genotypes and the miR-146a expression level. It would be of great interest to explore how polymorphism influences the mature miR-146a expression in HCC.

Concerning the relationship between miR-146a expression and clinicopathological parameters, Karakatsanis et al. ([@CIT0031]) found no association between miR-146a level and any clinicopathological feature. In the present study, miR-146a expression in stage III and IV was found to be lower than that in stage I and II. Moreover, miR-146a expression was down-regulated in the metastatic group compared with that in the non-metastatic group. Additionally, miR-146a expression was correlated with the status of portal vein tumor embolus and the number of tumor nodes. The status of portal vein tumor embolus and tumor nodes generally reflects tumor invasion and metastasis and disease deterioration. The results of our study reveal an obvious relation between miR-146a and the infiltration of tumor cells, migration, invasion, and metastasis of HCC. Hence, it may be valuable to clinically examine miR-146a expression for the prediction of metastasis and deterioration of HCC. Interestingly, we found that the miR-146a levels were lower in males than in females, which has not been reported before. Karakatsanis et al. ([@CIT0031]) studied the expression of miR-146a of 60 cases, with 16 females included, and no relationship was observed between miR-146a expression and gender. In the present study, there were only 16 female cases. Further studies in a larger cohort will be warranted to investigate the relationship between miR-146a level and gender. The potential mechanism could be related to the correlation between miR-146a and hormones, because gender-specific-miRNAs do exist ([@CIT0042]). However, this also needs further investigations.

The mechanisms of miR-146a being down-regulated in advanced stage of HCC could be related to different target genes. Different target genes of miR-146a have been demonstrated in several cancers. Rho-associated protein kinase (ROCK1) has been reported to be a target of miR-146a in androgen-independent PC3 prostate cancer cells. Transfection of miR-146a suppressed more than 82% of the expression of ROCK1, thereby markedly reducing cell proliferation, invasion, and metastasis in human bone-marrow endothelial cell monolayers ([@CIT0043]). The L1 cell adhesion molecule and SMAD family member 4 were both identified as novel targets of miR-146a in gastric cancer ([@CIT0044]). In gliomas, Notch1 was proved to be a direct target of miR-146a ([@CIT0046]). The NF-kappaB regulatory kinase interleukin 1 receptor-associated kinase 1 was verified as a target of miR-146a in pancreatic and breast cancer ([@CIT0047]). EGFR was also documented as a target of miR-146a in various cancers. Re-expression of miR-146a suppressed tumor growth or inhibited the invasive capacity of prostate, breast, pancreatic, and lung cancer cells ([@CIT0032]). Future work will hopefully discover possible target genes of miR-146a in HCC.

Conclusions {#ss8}
===========

Together with previous reports, the current observations strongly suggest that miR-146a acts as a tumor suppressor miRNA, which plays a vital role in the tumorigenesis and deterioration of human HCC. MicroRNA-146a expression in HCC FFPE samples could be a prognostic biomarker for HCC. Further *in vitro* and *in vivo* studies are planned to identify the role and mechanism of miR-146a in the malignant phenotype of HCC cells.
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